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Abstract: Since ancient times, people have attributed a variety of health benefits to 
moderate consumption of fermented beverages such as wine and beer, often without any 
scientific basis. There is evidence that excessive or binge alcohol consumption is 
associated with increased morbidity and mortality, as well as with work related and traffic 
accidents. On the contrary, at the moment, several epidemiological studies have suggested 
that moderate consumption of alcohol reduces overall mortality, mainly from coronary 
diseases. However, there are discrepancies regarding the specific effects of different types 
of beverages (wine, beer and spirits) on the cardiovascular system and cancer, and also 
whether the possible protective effects of alcoholic beverages are due to their alcoholic 
content (ethanol) or to their non-alcoholic components (mainly polyphenols). Epidemiological 
and clinical studies have pointed out that regular and moderate wine consumption (one to 
two glasses a day) is associated with decreased incidence of cardiovascular disease (CVD), 
hypertension, diabetes, and certain types of cancer, including colon, basal cell, ovarian, and 
prostate carcinoma. Moderate beer consumption has also been associated with these 
effects, but to a lesser degree, probably because of beer’s lower phenolic content. These 
health benefits have mainly been attributed to an increase in antioxidant capacity, changes 
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in lipid profiles, and the anti-inflammatory effects produced by these alcoholic beverages. 
This review summarizes the main protective effects on the cardiovascular system and 
cancer resulting from moderate wine and beer intake due mainly to their common 
components, alcohol and polyphenols.  
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1. Introduction 
Since ancient times wine has been closely associated with diet, particularly in Mediterranean 
countries [1], and for many years, moderate and regular consumption of wine has been associated with 
health benefits, with no scientific basis. However, over the last two decades, several studies around the 
world have demonstrated that intake of alcoholic beverages produces positive effects on antioxidant 
capacity, lipid profile and the coagulation system [2], that may explain the reduction in the risk of 
cardiovascular disease (CVD) [3,4], overall mortality [5] and other diseases observed in moderate 
drinkers. By contrast, alcohol abuse or binge drinking has undoubtedly been related to a large number 
of medical, social and work related problems (negative effects), including the development of alcohol 
dependence syndrome, several chronic diseases (liver cirrhosis, cardiomyopathy, encephalopathies, 
polyneuropathy, dementia) and accidents which eventually lead to death [6–8]. 
Several cohort studies have pointed out that light-to-moderate alcohol consumers have an increased 
survival compared to abstainers [9]. Current evidence also suggests the protective effects of moderate 
drinking on cardiovascular events including coronary heart disease (CHD) [10], ischemic stroke [11], 
peripheral arteriopathy and congestive heart failure [12]. Positive effects have also been reported for 
moderate alcohol consumption on cellular aging damage, cognitive function and dementia. These 
effects have been observed in a variety of patients, including diabetics, hypertensive subjects and those 
with previous CHD. 
Beneficial effects of moderate alcohol intake against atherosclerosis have been attributed to its 
antioxidant and anti-inflammatory effects, as well as to its actions on vascular function. In this 
framework, part of these effects may be attributed to polyphenols mainly contained in wine and beer, 
as these compounds exhibit antioxidant [13], anticarcenogenic [14], anti-inflammatory [15], 
hypotensive [16] or even anticoagulant properties [17]. 
Since the French paradox was described two decades ago [18], several studies have focused their 
attention on the components of red wine (mainly polyphenols and especially resveratrol) in order to 
explain the inverse association observed between moderate wine consumption and the incidence of 
CVD, as well as the different effects of the various types of alcoholic beverages (with or without 
polyphenols), thereby opening the debate of which type of alcoholic beverage is more cardioprotective 
than others. 
Although the chemical constituents of grapes and wine vary, similar beneficial effects have been 
observed in different varieties of red wine, with white wine seeming to benefit the cardiovascular 
system to a lesser extent than red wine. The greater health benefits of red wine may be related to its 
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higher polyphenolic content because of the distinctive production processes between red and  
white wine.  
The mechanisms responsible for the healthy effects of wine are extremely complex due to the many 
different pathways involved. Both alcohol and polyphenolic compounds have been extensively 
studied, despite the continued controversy as to which component is the most active [19]. The 
underlying mechanisms to explain these protective effects against CHD include an increase in  
high-density lipoprotein (HDL) cholesterol, a decrease in platelet aggregation, a reduction in the levels 
of fibrinogen and an increase in insulin sensitivity, which have been attributed to the ethanol content  
in wine. Other studies have provided evidence that wine exhibits beneficial properties which are 
independent of the presence of alcohol, and should be attributed to their polyphenolic content [20,21]. 
Similarly, the compounds found in beer have different biological activities demonstrated in enzymatic 
assays or cell cultures such as antioxidant [22], anticarcinogenic [23–25], anti-inflammatory [26], 
estrogenic [27] and even antiviral properties [28]. Different profiles of in vitro biological activity have 
been described for these compounds which, combined together, could have a synergistic effect.  
Therefore, the objective of this review is to summarize the main protective effects of moderate wine 
and beer consumption on CVD and cancer by way of their bioactive compounds.  
2. Polyphenolic Compounds in Wine and Beer  
Red wine polyphenols are a complex mixture of flavonoids (such as anthocyanins and flavan-3-ols) 
and nonflavonoids (such as resveratrol, cinnamates and gallic acid). Flavan-3-ols are the most 
abundant, with polymeric procyanidins (condensed tannins) composing up to 50% of the total phenolic 
constituents [29]. These compounds act as potent antioxidants as they reduce low-density lipoprotein 
(LDL) cholesterol oxidation, modulate cell signaling pathways, and reduce platelet aggregation. Red 
wine contains more polyphenols than white wine (around 10-fold) because during the wine making 
process, red wine, unlike white wine, is macerated for weeks with the skin which is one of the parts of 
the grape with the highest concentrations of phenolic compounds [30]. The concentrations in red wine 
range from around 1.2 to 3.0 g/L (Table 1). 
Both flavonoids and nonflavonoid phenolic compounds have been implicated in the protective 
effects of wine on the cardiovascular system. Nevertheless, the stilbene resveratrol has been one of the 
most extensively studied nonflavonoids as a critical constituent that contributes to the health benefits 
of red wine. In experimental studies, resveratrol exhibited both cardioprotective and chemopreventive 
effects, inhibiting LDL oxidation and platelet aggregation in animal studies. It also inhibits the growth 
of some tumor types and exhibits anti-inflammatory, antibacterial, antifungal, antiviral, neuroprotective, 
antiproliferative and anti-angiogenic activities [31,32]. However, the beneficial effects of moderate 
wine consumption may be attributed to the overall mix of all of its components and not to a specific 
action of one, such as resveratrol. Indeed, progress can be achieved in the field of the cardiovascular 
health effects of polyphenols when the one-dimensional antioxidant view of polyphenols is replaced 
by a view considering their multifaceted bioactivity, as polyphenols are versatile bioactives rather than 
mere antioxidants. 
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Table 1. Polyphenolic compounds in red wine. 
Phenolic compounds (mg/L) * 
 
Phenolic compounds (mg/L) * 
Anthocyanins  Kaempferol 2.3 
Cyanidin 3-O-(6′-acetyl-glucoside) 0.8 Kaempferol 3-O-glucoside 7.9 
Cyanidin 3-O-glucoside 2.1 Myricetin 8.3 
Delphinidin 3-O-(6′-acetyl-glucoside) 4.2 Quercetin 8.3 
Delphinidin 3-O-(6′-p-coumaroyl-glucoside) 1.8 Quercetin 3-O-arabinoside 4.9 
Delphinidin 3-O-glucoside 10.6 Quercetin 3-O-glucoside 11.4 
Malvidin 3-O-(6′-acetyl-glucoside) 35.2 Quercetin 3-O-rhamnoside 11.5 
Malvidin 3-O-(6′-caffeoyl-glucoside) 1.8 Quercetin 3-O-rutinoside 8.1 
Malvidin 3-O-(6′-p-coumaroyl-glucoside) 19.5 Hydroxybenzoic acids  
Malvidin 3-O-glucoside 99.7 2,3-Dihydroxybenzoic acid 0.8 
Peonidin 3-O-(6″-acetyl-glucoside) 4.7 2-Hydroxybenzoic acid 0.4 
Peonidin 3-O-(6′-p-coumaroyl-glucoside) 5.2 4-Hydroxybenzoic acid 5.5 
Peonidin 3-O-glucoside 8.2 Gallic acid 35.9 
Petunidin 3-O-(6′-acetyl-glucoside) 5.7 Gallic acid ethyl ester 15.3 
Petunidin 3-O-(6′-p-coumaroyl-glucoside) 3.9 Gentisic acid 4.6 
Petunidin 3-O-glucoside 14.0 Protocatechuic acid 1.7 
Pigment A 0.7 Syringic acid 2.7 
Pinotin A 2.2 Vanillic acid 3.2 
Vitisin A 3.1 Hydroxycinnamic acids  
Dihydroflavonols  2,5-di-S-Glutathionyl caftaric acid 28.6 
Dihydromyricetin 3-O-rhamnoside 44.7 Caffeic acid 18.8 
Dihydroquercetin 3-O-rhamnoside 9.7 Caffeoyl tartaric acid 33.5 
Flavanols  Ferulic acid 0.8 
(+)-Catechin 68.1 o-Coumaric acid 0.3 
(+)-Gallocatechin 0.8 p-Coumaric acid 5.5  
(−)-Epicatechin 37.8 p-Coumaroyl tartaric acid 11.8 
(−)-Epicatechin 3-O-gallate 7.7 Sinapic acid 0.7 
(−)-Epigallocatechin 0.6 Hydroxyphenylacetic acids  
Procyanidin dimer B1 41.4 4-Hydroxyphenylacetic acid 1.6 
Procyanidin dimer B2 49.7 Stilbenes  
Procyanidin dimer B3 94.7 d-Viniferin 6.4 
Procyanidin dimer B4 72.9 e-Viniferin 1.5 
Procyanidin dimer B7 2.7 Pallidol 2.0 
Procyanidin trimer C1 25.6 Piceatannol 5.8 
Procyanidin trimer T2 67.1 Piceatannol 3-O-glucoside 9.5 
Prodelphinidin dimer B3 1.1 Resveratrol 2.7 
Flavanones  Resveratrol 3-O-glucoside 6.2 
Hesperetin 0.5 Hydroxybenzaldehydes  
Naringenin 0.5 Protocatechuic aldehyde 0.5 
Naringin 7.5 Syringaldehyde 6.6 
Flavonols  Tyrosols  
Isorhamnetin 3.3 Hydroxytyrosol 5.3 
Isorhamnetin 3-O-glucoside 2.6 Tyrosol 31.2 
* Mean value of bibliographic data from Phenol-Explorer Database, Version 1.5.7 (INRA in collaboration with the 
Wishart Research Group) [33]. 
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Table 2. Polyphenolic compounds in beer. 
Phenolic compounds (mg/L) * 
 
Phenolic compounds (mg/L) * 
Simple Phenols  Flavanones  
Vinil-4-fenol ≤0.15 Isoxanthohumol 0.04–3.44 
Vinil-4-guayacol ≤0.55 8-Prenilnaringenin 0.001–0.24 
Etil-4-fenol ≤0.01 6-Prenilnaringenin 0.001–0.56 
Isoeugenol ≤0.04 6-Geranilnaringenin ≤0.074 
Tyrosol ≤40 Taxifolin ≤1.0 
Propil-4-siringol ≤0.2 Flavanols  
2,3-Dihydroxy-guaiacyl propan-1-one ≤0.034 (+)-Catechin ≤5.4 
Phenolic acids  (−)-Epicatechin ≤3.3 
4-Hydroxyfenilacétic ≤0.65 Catechin gallate 5–20 
Homovanillic 0.05 Epicatechin gallate 5–20 
Alquilphenols  Procyanidin B3 ≤3.1 
3-Metilcatecol ≤0.03 Prodelphynidina B3 ≤3.3 
4-Etilcatecol ≤0.01 Prodelphynidina B9 ≤3.9 
4-Metilcatecol ≤0.02 Procyanidin C2 0.3 
Vinil-4-fenol ≤0.15 Flavonols  
Benzoic acid derivatives  Kanpherol 16.4 
3,5-Dihydroxybenzoic 0.3 Kanpherol-3-rhamnoside ≤1.0 
2,6-Dihydroxybenzoic 0.9 Quercetin ≤10 
2-Hydroxybenzoic ≤2.0 3,7-Dimetilquercetin 0.003 
3-Hydroxybenzoic ≤0.3 Miricetin 0.007 
4-Hydroxybenzoic ≤9.6 Quercetin 3-O-Arabinoside 0.006 
Protocatecuic ≤0.3 Quercetina 3-O-Rutinoside 0.90 
Vanillic ≤3.6 Quercitrin ≤2.3 
Gallic ≤0.2 Isoquercitrin ≤1.0 
Siríngico ≤0.5 Rutin ≤1.8 
o-Vanillin ≤1.6 Isoflavones  
Siringic aldehyde ≤0.7 Daidzein ≤0.005 
Cinnamic acids  Genistein ≤0.01 
p-coumaric ≤1.2 Formononetin ≤0.004 
m-Coumaric ≤0.2 
 
Biochanin A ≤0.015 
o-Coumaric ≤1.5 Flavones  
5-Caffeoilquinic ≤0.8 Apigenin 0.042 
Caffeic ≤0.3 α-acids (humulones) 1.7 
Ferulic ≤6.5 Iso-α-acids (iso-humulones) 0.6–100 
Sinapic ≤0.7 Other polyphenols   
Chalcones  Catechol 0.1 
Xanthohumol 0.002–1.2 Pirogalol 0.3 
* Mean value of bibliographic data published by Estruch et al. 2011 [34]. 
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Beer is one of the most consumed alcoholic beverages around the world, being rich in nutrients 
such as carbohydrates, amino acids, minerals, vitamins and other compounds such as polyphenols. 
Hop (Humulus lupulus L.) is one of the raw materials of beer which serves as an important source of 
phenolic compounds. Dried hop cones contain about 14.4% of polyphenols, mainly phenolic acids, 
prenylated chalcones, flavonoids, catechins and pro-antocianidins [35]. Around 30% of polyphenols 
from beer comes from hops and 70%–80% originates from malt [36]. Moreover, hops provide a resin 
containing monoacyl phloroglucinols which become bitter acids during the development process of 
beer, such as α-acids (humulones) and iso-α acids. Table 2 details the bioactive compounds found in 
beer, mainly polyphenols. The structural classes of polyphenols in beer include simple phenols, 
benzoic acid derivatives and cinnamic acid, coumarins, catechins, di- and tri-oligomeric proanthocyanidins, 
prenylated chalcones and α- and iso-α acids derived from hops.  
Different profiles of in vitro biological activities have been described for these compounds which, 
in combination, exert a synergistic effect. However, to extrapolate these results and evaluate the in vivo 
physiological effects of beer consumption it is necessary to study their bioavailability in the body. The 
compounds found in beer have different biological activities demonstrated in vitro as antioxidant, 
anticarcinogenic, anti-inflammatory, estrogenic and antiviral. However, further studies in humans are 
needed to determine whether the plasma concentrations of these compounds, derived from moderate 
consumption of beer, have the same bioactivity observed in vitro. 
3. Effects of Alcohol and Polyphenols on the Cardiovascular System 
Although several epidemiological studies have shown a protective effect of moderate alcohol 
consumption on the incidence of cardiovascular events, the exact mechanisms involved are still not 
well known. Up to now, lower risk of myocardial infarction in both sexes has been related to the 
effects of moderate alcohol consumption on lipoproteins (HDL), coagulation (fibrinogen) and 
sensitivity to insulin (haemoglobin A1c) [11]. The modulation of circulating cholesterol is the best 
established protective factor of alcohol intake [37]. Except in people with liver impairment, alcohol 
ingestion raises serum HDL-cholesterol levels by incompletely understood pathways [38]. Inverse 
relations of HDL-cholesterol and CHD risk operate substantially via removal of lipid deposits in large 
blood vessels. HDL also binds with cholesterol in the tissues and may aid in preventing LDL 
cholesterol oxidation. The net effect is a reduction in the plaque building in walls of large blood 
vessels, such as coronary arteries. One study suggested that the major HDL subfractions, HDL2 and 
HDL3, were involved. While HDL3 may be strongly related to alcohol intake, both HDL fractions are 
related to lower CHD risk [39]. Nevertheless, a recent meta-analysis has questioned this hypothesis 
suggesting that HDL is not one of the most important intermediate variables in the possible causal 
pathway between moderate alcohol intake and CHD [40]. 
Since CHD is also considered a disease related to oxidative stress, several studies have analyzed  
the effects of different alcoholic beverages on oxidant status. In a cross-sectional study, alcohol 
consumption showed a direct relationship with the plasma concentration of in vivo oxidized low 
density lipoproteins (LDL) [41], while another study observed that the levels of the DNA oxidation 
marker 8-oxo-deoxyguanosine decreased with the amount of alcohol consumed [42]. The final effect 
probably depends on the total amount of alcohol consumed. Thus, in interventional studies a change in 
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daily beer alcohol consumption from moderate-heavy to light intake lowered plasma F2-isoprostanes 
in healthy non-smoking men [43]. Ethanol metabolism can produce free radicals and reduce the levels 
of glutathione, the major cellular protection against oxidative stress. However, in addition to alcohol, 
wine and beer contain polyphenols which could confer beneficial health properties compared to other 
classes of alcoholic beverages [44,45]. In a recent study comparing the antioxidant effects of a  
polyphenol-rich alcoholic beverage (red wine) with those of a polyphenol-free alcoholic beverage (gin), 
it was observed that compared to gin, red wine reduced plasma superoxide dismutase activity and 
malondialdehyde levels, as well as increased lag phase time of LDL oxidation analysis, suggesting that 
red wine has greater antioxidant effects, probably due to its high polyphenolic content [46].  
Triglycerides may play an independent role in the risk of CHD. A subset of heavy drinkers has a 
substantial increase in triglyceride levels, but this is infrequently seen in light to moderate  
drinkers [47]. Alcohol (ethanol) inhibits several promoters of clotting, including platelet stickiness and 
fibrinogen levels [38]. In addition, moderate alcohol consumption also affects the fibrinolytic system. 
In fact, it increases plasminogen activator inhibitor activity and reduces plasminogen activator activity 
in the postprandial period (five hours after eating), a fact that may explain the reduction in the early 
morning cardiovascular events observed in moderate drinkers who consume alcohol with dinner [48].  
A recent meta-analysis of prospective observational studies has observed that moderate alcohol 
consumption lowers the risk of type 2 diabetes [49]. In addition, randomized clinical trials have also 
demonstrated that moderate alcohol intake has beneficial effects on insulin concentrations and insulin 
sensitivity in non-diabetic patients [50], suggesting that moderate alcohol consumption decreases the 
risk of CVD and type 2 diabetes by improving insulin sensitivity. On the other hand, the results of 
some experimental studies have suggested that moderate consumption of wine could also protect 
endothelial cells from injury produced by hyperhomocysteinemia [51], although further studies are 
needed on this issue. 
The previously mentioned effects of ethanol, mainly those on lipoproteins and clotting factors seem 
to account for 50% of the beneficial effect of alcohol consumption in the prevention of atherosclerosis. 
However, to explain the totality of the antiatherosclerotic effects of alcohol it is necessary to resort to 
additional mechanisms. 
Other studies have shown that alcohol and individual polyphenols modulate EC fibrinolytic protein 
(t-PA, u-PA, PAI-1, u-PAR and Annexin-II) expression at the cellular, molecular and gene levels to 
sustain increased fibrinolytic activity [52]. 
In summary, the mechanisms by which alcoholic beverages exert their actions involve lipid 
regulation and systemic anti-inflammatory effects. The alcohol component (ethanol) increases  
HDL-cholesterol levels, inhibits platelet aggregation, and reduces systemic inflammation. However, 
red wine provides additional benefits to those of other alcoholic beverages probably due to its higher 
polyphenolic content, by decreasing blood pressure, inhibiting the oxidation of LDL particles and 
other favorable effects on the cellular redox state, improving endothelial function, inhibiting platelet 
aggregation, reducing inflammation and cell adhesion and activating proteins that prevent cell death. 
These effects are weaker in the case of white wine or beer probably due to the lower concentration of 
polyphenols compared to red wine. 
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4. The Effects of Wine and Beer on the Cardiovascular System 
4.1. Epidemiological Studies 
In previous studies evaluating whether different alcoholic beverages protect against CVD, a  
J-shaped relationship was found for increasing wine consumption and vascular risk [53]. A recent 
meta-analysis including a parallel and separate evaluation of wine and beer consumption indicated a 
similar protective effect for beer and wine against cardiovascular risk [54]. On the contrary, no 
statistically significant association with vascular events was apparent for the intake of spirits, the type 
of alcoholic drink with the highest alcohol concentration and the lowest polyphenolic concentration, 
suggesting that the polyphenolic constituents found in wine or beer could be (mainly) responsible for 
the beneficial effect of alcoholic beverages on vascular events [55–60]. 
A great number of epidemiologic studies have evaluated the effects of the three main types of 
alcoholic drinks (wine, beer and distilled drinks) on the cardiovascular system. Some studies such as 
the Copenhagen City Heart Study [53] or that carried out in the east of France [61] found a high 
significant relationship between low or moderate wine consumption and a lower mortality by CVD, 
whereas in many other great epidemiologic studies, especially those based on the registries of the 
Nurse’s Health Study [62] or the Health Professionals Follow-up Study [11], no differences were 
found between the protective effects of moderate consumption of the different types of drink 
consumed. In the meta-analysis by Di Castelnuovo et al., 2010 [59], the authors analyzed the effects of 
the consumption of wine and beer on cardiovascular risk separately, concluding that the relative risk of 
associated vascular disease with wine consumption was of 0.68 (confidence interval 95% 0.59 to 0.77) 
compared with non-drinkers. 
However, in other prospective studies, it has been observed that the moderate consumption  
of alcoholic drinks with a high alcoholic grade (liquors and distillates) also has a cardioprotector  
effect [63]. This fact explains that part of the beneficial effects of alcoholic beverages is largely due to 
ethanol, and not to the other specific components of each type of drink. Thus, the question as to 
whether the beneficial effects of alcoholic beverages depend on the alcoholic or non-alcoholic 
components of these beverages remains open and may not be answered on the basis of the results of 
epidemiological studies alone (see later).  
Finally, other confounding factors should be taken into account in the study of the relationship 
between alcohol consumption and health. As the incidence of coronary disease is low in men and 
women under 40 and 50 years of age, respectively, a recent study concluded that young adults who 
consume alcohol moderately also presented a significant reduction of the risk of coronary disease 
compared with abstainers, although the protective effects are lower than those observed in middle-aged 
adults or older adults [64]. 
Other studies have pointed out that the lower mortality and the reduced risk of ischemic cardiopathy 
observed in moderate drinkers could be due to other factors such as the maintenance of an uncommon 
lifestyle (Mediterranean diet) or due to genetic factors that also play an important role in the protection 
of moderate alcohol consumption against CVD [2]. These epidemiological studies have controlled 
both the classical vascular risk factors and other confounding factors, such as diet, exercise and certain 
demographic and psychosocial characteristics, leaving little doubt as to the validity of results from an 
epidemiological point of view.  
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However, to obtain the best scientific evidence, the conclusions obtained from the results of  
meta-analyses or systematic reviews should only be based on randomized clinical trials. It would, 
therefore, be necessary to analyze a number of randomised studies with long-term interventions in 
which hard end-points (cardiovascular mortality, non-fatal acute myocardial infarction and non-fatal 
stroke) have been evaluated. In the absence of these studies, the findings of epidemiological studies 
cannot be considered definitive, especially after striking differences have been observed between the 
results of epidemiological and intervention studies, assessing, for example, the effectiveness of 
antioxidant vitamins on ischemic CHD [65]. 
For more than one decade it has been known that atherosclerosis is not only due to simple lipid 
accumulation in the arterial wall of certain zones of the vascular system, but rather, this is 
accompanied by a chronic inflammatory reaction of low intensity that contributes to the formation of 
atheroma plaques [66]. The biochemical and cellular mechanisms that lead to the beginning and 
progression of atherosclerosis have been widely studied [67]. This complex process involves the 
participation of very diverse cells (endothelial cells, smooth muscular cells, monocytes, lymphocytes 
and platelets), adhesion molecules (selectins, integrins and those pertaining to the super family of 
immunoglobulins), cytokines (interleukin (IL)-6, monocyte chemotactic peptide-1) and enzymes 
(metalloproteases). The first stage of atherosclerosis consists of the adhesion of monocytes and 
lymphocytes to the endothelium facilitated by adhesion molecules. Later, these cells migrate to the 
sub-endothelial space where they accumulate lipids and produce cytokines, growth factors and 
hydrolytic enzymes, which also induce a migration and proliferation of smooth muscle cells in this 
sub-endothelial space. The perpetuation of this process gives rise to the formation of atheroma plaque 
that becomes symptomatic when fissure (unstable plaque) is produced and induces the generation of 
thrombus on ulcerated plaque which, if not quickly degraded (fibrinolysis), may significantly occlude 
the vascular lumen and give rise to clinical events such as acute myocardial infarction or ischemic 
stroke [68]. Therefore, in order to know the role of alcohol consumption on the initiation and 
progression of atherosclerosis, the effect of alcohol on all the factors participating in the different 
stages of this process should be analyzed.  
4.2. Clinical Trials 
As stated before, although there is general consensus concerning the lower risk for ischemic disease 
in moderate drinkers, there are discrepancies as to whether this cardioprotective effect is due to the 
ethanol in alcoholic beverages or to their non-alcoholic content, mainly polyphenolic compounds 
contained in some alcoholic beverages, especially wine or beer. Part of these issues may be solved 
only by the performance of well-designed randomized clinical trials analyzing the in vivo effects of 
wine and/or beer (in comparison with other alcoholic beverages). Randomized cross-over clinical trials 
will allow monitoring the diet of the subjects included and will eliminate the effects of antioxidants 
and other healthy compounds from the food, mainly fruits and vegetables. Up to now, the results of the 
different clinical trials have been contradictory.  
Thus, de Rijke et al. [69] examined the effect of the non-alcoholic components of red wine by 
reducing their alcohol content. The de-alcoholized red wine did not affect the susceptibility of LDL to 
copper-mediated oxidation. The results of this study did not show a beneficial effect of red wine 
Nutrients 2012, 4 768 
 
consumption on LDL oxidation. By contrast, the study performed by Fuhrman, Lavy and Aviram [70] 
concluded that the consumption of red, but not white wine, by healthy volunteers reduced the 
propensity of LDL to undergo lipid peroxidation. However, some methodological problems related to 
the sample size, the sex of the subjects and dose or type of alcoholic beverage may be raised on 
analysis of these studies. In order to solve these issues, recent clinical trials have compared the effects 
of red wine, an alcoholic beverage with high polyphenol content, with gin, an alcoholic beverage 
without polyphenols. In this setting, Estruch et al. 2011 [46] showed that ethanol itself may exert 
significant beneficial effects on the cardiovascular system, mainly by increasing HDL-cholesterol and 
decreasing oxidation of LDL. However, red wine provided additional benefits due to its higher 
antioxidant effects, by decreasing serum malondialdehyde, blood superoxide dismutase activity and 
oxidized LDL plasma levels. 
On the other hand, since atherosclerosis is considered an inflammatory disease, other studies have 
analyzed the effects of moderate consumption of wine and gin on inflammatory biomarkers [60,71]. 
Randomized clinical trials including wine and other alcoholic beverages without polyphenols showed 
anti-inflammatory effects by reducing plasma fibrinogen and IL-1α levels. Again, however, wine 
showed additional effects by decreasing highly sensitive C-reactive protein, as well as monocyte and 
endothelial adhesion molecules [60,72]. Related to the latter, new findings from a randomized, 
crossover trial developed with 67 high-risk male volunteers consuming red wine, the equivalent amount 
of de-alcoholized red wine, or gin, revealed that alcohol increased IL-10 and decreased  
macrophage-derived chemokine concentrations, whereas the phenolic compounds of red wine 
decreased serum concentrations of intercellular adhesion molecule-1, E-selectin, and IL-6 and 
inhibited the expression of lymphocyte function-associated antigen 1 in T-lymphocytes and 
macrophage-1 receptor, Sialyl-Lewis X, and C-C chemokine receptor type 2 expression in monocytes. 
Both ethanol and phenolic compounds of red wine downregulated serum concentrations of CD40 
antigen, CD40 ligand, IL-16, monocyte chemotactic protein-1, and vascular cell adhesion  
molecule-1 [73]. Other studies performed in women observed that daily doses of 15–20 g of alcohol as 
red wine were sufficient to elicit anti-inflammatory effects similar to those observed in men who 
consumed higher doses of wine [74]. 
Many researchers have investigated the kinetics and extent of polyphenol absorption by measuring 
plasma concentrations and/or urinary excretion among adults after the ingestion of a single dose of 
polyphenol, provided as a pure compound or whole beverage. Subjects who showed higher  
absorption of polyphenols showed lower serum concentrations of inflammatory biomarkers than their 
counterparts [75]. Table 3 summarizes data from several relevant reviews about levels of polyphenolic 
metabolites in plasma and urine after wine or beer consumption. The results clearly show wide 
variability in the bioavailability of the different polyphenols. The polyphenols that are most well 
absorbed in humans are isoflavones and gallic acid, followed by catechins, flavanones and quercetin 
glucosides, with different kinetics. The least well-absorbed polyphenols are proanthocyanidins, the 
galloylated catechins and the anthocyanins. Data for other polyphenols are still too limited. Moreover, 
metabolism by the gut microbiota probably plays a major role in the biological activity of many 
polyphenols as in the case of prenylflavonoids of beer. 
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Table 3. Main polyphenolic metabolites described in literature from wine and beer.  
Polyphenol 
group 
Polyphenol metabolite Source Dose per day 
No. 
subjects 
Urine Plasma 
Ref. 
Urinary excretion Tmax (h) Mean Concentration Tmax (h) 
Flavanols 
Catechin 
Red wine 35 mg (120 mL) 9  3.1 0.091 μmol/L 1.5 [76] 
Red wine 35 mg (120 mL) 9  3.2 0.077 μmol/L 1.44 [77] 
Red wine 35 mg (120 mL) 9 3%–10% of intake    [78] 
(+)-Catechin Red wine 120 mL 9    1.6 [76] 
3′-O-Methylcatechin Red wine 120 mL 9    1.2 [76] 
Anthocyanins 
Total anthocyanins Red wine 218 mg (300 mL) 6 1.5%–5.1% of intake/12 h 6   [79] 
Malvidin 3-glc Red wine 68 mg (500 mL) 6 0.016% of intake/6 h <3 0.0014 μmol/L 0.83 [80] 
Hydroxycinnamic 
acids 
Caffeic acid 
Red wine 
0.9–1.8–2.7 mg  
(100, 200, 300 mL) 
5   0.007–0.027 μmol/L 1 [81] 
Red wine 1.8 mg (200 mL) 10   0.037–0.060 μmol/L 0.5–1 [82] 
Red wine 55 μg/kg bw 12   0.084 μmol/L 2 [83] 
Red wine 5 mL/kg bw 12     [83] 
Beer 500 mL 10   0.05–0.07 μmol/L 1 [83] 
Ferulic acid Beer 500 mL 10   0.11 μmol/L 1 [83] 
4-Hydroxyphenylacetic acid Beer 500 mL 10  8 1.4–1.17 μmol/L 0.5–1 [84] 
Vanillic acid Beer 500 mL 10   0.11 μmol/L 1 [84] 
p-Coumaric acid Beer 500 mL 10   0.05–0.07 μmol/L 1 [84] 
Hydroxybenzoic 
acids 
Gallic acid Red wine 4 mg (300 mL) 2   
0.22 GA + 1.1 4-MeGA 
+ 0.25 3-MeGA μmol/L  [85] 
Methylgallic acid Red wine 47 μg/kg bw 12   0.18 4-MeGA μmol/L 2 [83] 
4-O-Methylgallic acid Red wine 5 mL/kg bw 12     [83] 
Stilbenes 
Cis-resveratrol 3-sulfate Red wine 250 mL 5 221.2 nmol/g creatinine 4   [86] 
Trans-resveratrol  
3-O-glucuronide 
Red wine 250 mL 5 179.2 nmol/g creatinine 4   [86] 
Trans-resveratrol  
4′-O-glucuronide Red wine 250 mL 5 59.6 nmol/g creatinine 4   [86] 
Cis-resveratrol 4′ sulfate Red wine 250 mL 5 9294.2 nmol/g creatinine 4   [86] 
Trans-Resveratrol 3-sulfate Red wine 250 mL 5 74.7 nmol/g creatinine 4   [86] 
Trans-Resveratrol 4′-sulfate Red wine 250 mL 5 2.4nmol/g creatinine 4   [86] 
Cis-resveratrol  
3-O-glucuronide 
Red wine 250 mL 5 893.5 nmol/g creatinine 4   [86] 
Cis-resveratrol  
4′-O-glucuronide Red wine 250 mL 5 355.8 nmol/g creatinine 4   [86] 
Tmax, time when Cmax is achieved; Cmax: maximal concentration; GA, gallic acid; MeGA, methylgallic acid; bw, body weight. 
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All these data provide strong biological plausibility to the epidemiological observations that 
moderate wine drinking reduces cardiovascular events. However, it should be taken into account that, 
although moderate wine intake reduces the risk of CHD, even low alcohol consumption in women may 
increase the risk of certain cancers, especially breast cancer [87]. 
In conclusion, moderate consumption of wine exerts a protective effect on biomarkers related to the 
progression and development of atherosclerosis due to its alcoholic (ethanol) and non-alcoholic 
(polyphenols) content. Women and those subjects with high polyphenol absorption are more sensitive 
to the healthy effects of wine. 
Beer, despite its lower antioxidant and anti-inflammatory activity, also exerts a protective role 
against CVD. However, most studies addressing this issue are based on in vitro assays and animal 
studies, which have shown that the compounds derived from benzoic and cinnamic acids, catechins, 
procyanidins, humulones [23] and prenil-chalcones [88] are the major contributors to the antioxidant 
capacity of beer. It has also been observed that xanthohumol inhibited the oxidation of LDL in vitro 
induced by Cu2+ [89], as well as lipid peroxidation of liver microsomes in rats [90]. 
The anti-inflammatory mechanisms of bioactive compounds of beer are mainly due to the inhibition 
of inducible nitric oxide synthase (iNOS) and inhibition of the activity of cyclooxygenase 1  
(COX-1) [23,26]. The main anti-inflammatory effect mediated by inhibition of iNOS induction seems 
to be due to xanthohumol. Moreover, xanthohumol and humulone produce an anti-inflammatory effect 
through inhibition of endogenous synthesis of prostaglandin E2 via COX-2 inducible by TNFα [23,26]. 
5. Role of Wine and Beer in Cancer Prevention  
The consumption of alcohol has been identified as one of the top-10 risks contributing to the 
worldwide burden of disease. The International Agency for Research on Cancer (IARC) has classified 
ethanol as carcinogenic to humans [91]. Thus, the carcinogenic effects of alcoholic beverages are 
essentially due to their ethanol content and increase with the amount of alcohol drunk. Although the 
interpretation of data obtained in epidemiological studies is difficult due to confounding factors such 
as smoking, diet, hormone-replacement therapy and family history, the risks are essentially due to the 
ethanol content of alcoholic beverages. However, there is evidence that moderate wine consumption 
may decrease the risk of several cancers, including colon, basal cell carcinoma, ovarian and prostate 
cancer [92,93].  
Consumption of approximately 1 glass of wine daily was associated with a decreased risk of 
developing Barrett’s esophagus, a precursor to esophageal adenocarcinoma, when compared to heavy 
drinkers or non-drinkers [94]. A meta-analysis found that modest wine consumption had an inverse 
association for developing lung cancer, for both average wine consumption of less than one drink per day 
(RR, 0.77; 95% CI, 0.59–1.00) and one drink or greater per day (RR, 0.78; 95% CI, 0.60–1.02) [95]. A 
study of female non-Hodgkin’s lymphoma patients found a significantly better five-year overall 
survival (75% vs. 69%) and five-year disease free survival (70% vs. 67%) in occasional wine drinkers 
vs. abstainers [96]. Compared to non-drinkers, women who drank wine for at least 25 years previously 
were 33% less likely to die and 26% less likely to experience a relapse or develop a secondary cancer 
over the five-year period following diagnosis.  
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A large percentage of the literature on the cancer-preventing effects of wine are focused on one 
compound in particular: resveratrol. Many comprehensive reviews have been written on this  
subject [31,97,98]. Wine may inhibit carcinogenesis by acting as an antioxidant, anti-inflammatory 
agent, antimutagen, antimetastatic, anti-angiogenic, antidifferentiation, antiproliferative, and 
proapoptotic agent. It modulates signal transduction, immune response, transcription factors, growth 
factors, cytokines, caspases, interleukins, prostaglandin synthesis and cell cycle-regulating proteins. 
However, although there are few doubts as to the beneficial effects of moderate drinking on the 
cardiovascular system, only a limited number of reports concerning alcohol and cancer have provided 
results in favor of a reduced risk of death by cancer. According to the data of the Million Women  
study [87] even light to moderate levels of alcohol consumption were predictive of an increased risk of 
several common cancers, mainly those of the breast. It has been suggested that alcohol intake increases 
circulating levels of estrogen and the production of reactive oxygen species during alcohol 
metabolism, inducing DNA damage that results in breast cancer [99,100]. A recent study has reported 
that alcohol intake, the genes involved in alcohol metabolism and their interaction, increase the risk of 
breast cancer in post-menopausal women [101]. In relation to the type of beverage (beer, wine or spirits), 
a prospective cohort study has reported that total alcohol intake of more than 27 drinks per week 
increases breast cancer risk in premenopausal women independently of the type of alcoholic beverage 
consumed [102]. However, a low to moderate alcohol intake was not associated with increased 
mortality after breast cancer in a cohort of middle-aged women previously diagnosed with breast 
cancer [103]. Additionally, the drinking pattern seems important in terms of alcohol-breast cancer 
association as some authors have suggested that low and regular wine consumption does not increase 
breast cancer risk [104]. 
Several components of wine (mainly resveratrol) have shown anticarcinogenic properties in 
experimental studies [105]. Those have been supported by its ability to inhibit proliferation of a wide 
variety of human tumor cells in vitro as well as implanted tumors, usually in mice [97,106]. However, 
it should be emphasized that these results are measurements of resveratrol responses on human cancer 
cells in culture, or taken as conclusions from epidemiological studies, rather than the results of clinical 
trials with cancer patients. 
In the case of beer, xanthohumol is the best studied anticarcinogenic. It acts by inhibiting the 
metabolic activation of procarcinogenics, detoxifying enzyme inducers of carcinogens [25] and 
inhibiting tumor growth in early stages through inhibition of angiogenesis and inflammatory signals. 
Other compounds in beer with anticarcinogenic capacity are 8-prenilnaringenin, isoxanthohumol  
(having 10–20-fold lower concentrations than the effective doses in humans in beer) and other 
prenilflavonoids, as well as the flavanones, humulones and proantocianidins [24]. Considering that the 
bioavailability of the phenolic compounds of beer is very low, their anticarcinogenic effects are 
somewhat controversial as many epidemiological studies have shown [107,108]. However, polyphenols 
from beer can reach low but effective concentrations in the colon, acting as local anti-carcinogenic 
agents. The iso-α-acids (humulones) represent one of the most abundant groups of polyphenols in beer 
and also possess antitumor activity. It has also been described that cohumola, n-humulone and 
adhumulona activate receptors of α peroxisome proliferation (PPAR α), having potential activity in 
preventing cancer [23].  
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Several epidemiological studies have investigated the potential role of beer as a cause of cancer due 
to the detection of volatile nitrosamines in beer, although amounts have been reported to be lower in 
more recent decades because of changes in the beer-making process [109–111]. Since most 
epidemiological studies refer to long-term alcohol consumption, these studies cover, in part, periods  
of time before changes were made in the malting process. On the other hand, beer consumption  
(10 g alcohol/day) was reported to significantly decrease the risk of prostate cancer in comparison with 
non-drinking of beer in a Canadian study including 1253 subjects [112,113]. 
Malt-derived beer components require further investigation. Studies with melanoidins, i.e., polymeric 
and colored final products of the Maillard reaction which are formed non-enzymatically during the 
roasting of malt, indicate peroxyl radical scavenging potential [114,115]. Melanoidin fractions with a 
relatively high molecular weight (10→200 kDa) also weakly induced NADPHcytochrome C reductase 
and size-dependently modulated GST activities in the Caco-2 colon cancer cell line [116]. The 
information available illustrates that beer is an extremely complex mixture of bioactive substances. 
Therefore, a thorough exploration of the chemopreventive activities of isolated prominent beer 
components seems to make eminent sense. Nevertheless, future studies should also focus on defined 
combinations to explore whether the mixture can be more efficacious than the single components. 
Thus, the issue of alcohol and cancer is wide open and new studies are needed. Since self-reported 
data on alcohol consumption in epidemiological studies may not be reliable, especially in women, 
clinical studies on the effects of alcohol on health should be based on specific and accurate biomarkers 
of alcohol or wine/beer consumption such as ethanol (ethylglucoronide or ethylene glycol) or 
polyphenolic metabolites, respectively, in urine. 
6. Conclusions 
Sufficient evidence supports a significant inverse association between regular and moderate wine 
consumption and vascular risk, particularly red wine, and a similar relationship is reported for beer 
consumption, while lower protection is described for the consumption of any spirituous beverage. 
Clinical and epidemiological studies indicate that it is mainly red wine which may protect against 
CVD, atherosclerosis, hypertension, certain types of cancer, type 2 diabetes, neurological disorders 
and metabolic syndrome.  
There is evidence that certain polyphenols, such as resveratrol, anthocyanins, flavonols and 
catechins in wine provide an abundance of health benefits. Furthermore, rather than polyphenols 
themselves, their metabolites might be the real key players in cardiovascular and cancer protection. In 
beer, xanthohumol and its metabolites isoxanthohumol and phytoestrogen 8-prenylnaringenin also 
provide healthy properties such as anticarcinogenic, anti-invasive, anti-angiogenic, anti-inflammatory 
and antioxidant effects. The complexity increases when considering that each subject may metabolize 
the beverage differently, making it impossible to establish one specific constituent as being critical 
from a health standpoint.  
It must be emphasized that the benefits associated with red wine and beer are dependent upon 
regular and moderate consumption. Although general recommendations are one drink (150 mL of wine 
or 10 g of alcohol) daily for women and two drinks (300 mL of wine or 20 g of alcohol) daily for men, 
individual ideals may vary based on age, gender, genetics, body type and drug/supplement use. These 
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different recommended daily doses of alcohol between genders are explained by the fact that women 
are more sensitive to the effects of alcohol on the body. In addition, any healthy effects of wine and 
beer are greater in combination with a healthy diet. The health benefits associated with the 
Mediterranean diet, which combines moderate wine and beer consumption with a diet rich in fruits, 
vegetables and whole grains, suggests that polyphenols have synergistic effects with compounds found 
in other groups of foods.  
Although alcohol consumption is a two-sided coin, moderate alcohol consumption especially of 
wine has demonstrated the provision of a protective role for the cardiovascular system and in some 
types of cancer. Most medical professionals as well as the American Heart Association agree that 
heavy drinkers or alcohol abstainers should not be encouraged to drink wine for health reasons. Wine 
consumption should not replace a healthy lifestyle. However, light-to-moderate wine drinkers, without 
medical complications, may be assured that their wine consumption is a healthy habit. 
Nevertheless, more randomized clinical trials focused on elucidating the mechanisms of the action 
of alcohol and polyphenols are needed. 
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